Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15551380 | 0.94 | LIPE (0.44) | HPGDJAK1KMT2AALDH1A1LIPE | |
| SCHEMBL24518383 | 0.94 | LIPE (0.44) | HPGDJAK1KMT2AALDH1A1LIPE | |
| SCHEMBL28019652 | 0.94 | LIPE (0.44) | HPGDJAK1KMT2AALDH1A1LIPE | |
| SCHEMBL28960167 | 0.87 | CA2 (0.44) | HPGDJAK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30937160 | 0.82 | MEN1 (0.39) | JAK1MEN1KMT2ASMN1; SMN2LIPE | |
| SCHEMBL18389969 | 0.82 | HTR1A (0.50) | ALDH1A1HTTHSD11B1 | |
| SCHEMBL1561215 | 0.81 | LMNA (0.49) | HPGDSMN1; SMN2ALDH1A1LIPEHTT | |
| SCHEMBL8541139 | 0.80 | CHRNB2 (0.47) | JAK1MEN1KMT2ASMN1; SMN2USP30 | |
| SCHEMBL4375383 | 0.80 | MAPT (0.50) | MEN1KMT2ASMN1; SMN2ALDH1A1LIPE | |
| SCHEMBL30967383 | 0.80 | CA2 (0.44) | HPGDKMT2AALDH1A1LIPEHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | LUNAC THERAPEUTICS LTD (GB) | 2024-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F7 | HPGD 1326/4885JAK1 3244/4885MEN1 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.